PubMed
Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin
Winbanks CE, Wang B, Beyer C, et al. American Journal of Physiology — Endocrinology and Metabolism. 2009
Compare
Follistatin 344 vs Pentosan Polysulfate
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Follistatin 344
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Sleep
6
Energy
3
Self-reported dose per injection
Median bucket: 50–100 mcg · Most common: 50–100 mcg
Reports span 50–200 mcg
50–100
4
100–200
2
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Pentosan Polysulfate
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 0% · Mixed 17% · Unfavorable overall 83%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Digestive upset
6
Self-reported dose per injection
Median bucket: 0–25 mcg · Most common: 0–25 mcg
Reports cluster around 0–25 mcg
0–25
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Sources (9)
Published sources linked on the Follistatin 344 and Pentosan Polysulfate wiki pages.
- Wiki study page →Source
- Wiki study page →Source
ClinicalTrials.gov
Follistatin / Myostatin inhibition studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis
Sugiyama M, Yamaki A, Furuya M, et al. American Journal of Physiology — Endocrinology and Metabolism. 2010
- Wiki study page →Source
PubMed
Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy
Sepulveda PV, Bush ED, Bhattacharya A, et al. Scientific Reports. 2015
- Wiki study page →Source
PubMed
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
Stefanakis K, Kokkorakis M, Mantzoros CS. Metabolism: clinical and experimental. 2024
- Wiki study page →Source
FDA Drug Label
ELMIRON (pentosan polysulfate sodium) — Prescribing Information
Janssen Pharmaceuticals. FDA Drug Label. 1996
- Wiki study page →Source
PubMed
Pentosan polysulfate sodium for knee osteoarthritis: systematic review
Bannuru RR, Osani MC, Vaysbrot EE, et al. Osteoarthritis Cartilage. 2020
- Wiki study page →Source
PubMed
New therapeutic strategies in osteoarthritis
Siddiq MAB, Oo WM, Hunter DJ. Joint bone spine. 2024
- Wiki study page →Source
PubMed
The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment
Ghosh P. Seminars in arthritis and rheumatism. 1999